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Introduction
A major challenge in rare diseases is conducting clinical
trials with sufficient power to inform best clinical practice
when anticipated sample sizes are small. Historically, this
has been a major barrier in rare paediatric autoimmune
diseases. Bayesian methodology can be used to augment
the sparse therapeutic data obtained from clinical trials in
these circumstances.
Objectives
We elicited expert prior opinion for a future Bayesian ran-
domised controlled trial for a rare inflammatory paediatric
disease, polyarteritis nodosa (MYPAN, Mycophenolate
mofetil for polyarteritis nodosa).
Methods
A Bayesian prior elicitation meeting was convened.
Participating experts were drawn from across the EU and
Turkey. Opinion was sought on the probability that a
patient in the MYPAN trial treated with cyclophospha-
mide would achieve disease remission within 6-months,
and on the relative efficacies of mycophenolate mofetil
and cyclophosphamide. Expert opinion was combined
with previously unseen data from a recently completed
randomised controlled trial of mycophenolate mofetil
versus cyclophosphamide in anti-neutrophil cytoplasmic
antibody associated vasculitis.
Results
A pan-European group of fifteen experts participated in
the elicitation meeting. Consensus expert prior opinion
was that the most likely rates of disease remission within
6 months on cyclophosphamide or mycophenolate mofetil
were 74% and 71% respectively. This prior opinion will
now be taken in to account and will be modified to formu-
late a Bayesian posterior opinion when data from
40 patients completing the trial randomised at a 1:1 ratio
to either receive cyclophosphamide or mycophenolate
mofetil are available.
Conclusion
We suggest that this methodological template could be
applied to trial design for other rare diseases, and is of
particular relevance to rare autoimmune conditions that
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